ConductScience.org, home

Comparison · NCT02329964-sae

R-S Group vs S-C-N Group: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. R-S Group vs S-C-N Group: serious adverse events. Trial comparisons, record NCT02329964-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02329964-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0876wilson
Risk in group 2000.0876wilson
Risk difference, group 1 minus group 20-0.08760.0876newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1R-S Group
Rocuronium-Sugammadex group~1. Induction agent :~ * IV Propofol 1.5-2.5 mg/Kg and fentanyl 1.5mcg/kg~2. During induction of anesthesia, as muscle relaxant agent~ * Rocuronium 1mg/kg~3. After endotracheal intubation~ * normal saline(0.025 ml/kg)~4. Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery~ * Rocuronium 0.15mg/kg~5. Relaxant agent reversal. at the the end of surgery.~ * sugammadex 2mg/kg
040EG000
Group 2S-C-N Group
Succinylcholine-Cisatracurium-Neostigmine group~1. Induction agent :~ * IV Propofol 1.5-2.5 mg/Kg and fentanyl 1.5mcg/kg~2. During induction of anesthesia, as muscle relaxant agent~ * Succinylcholine 1mg/kg~3. After endotracheal intubation,~ * Cisatracurium 0.08mg/kg~4. Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery~ * Succinylcholine 10mg~5. Relaxant agent reversal. at the appearance of second TOF twitch (T2).~ * Neostigmine 0.2 mg/kg with atropine 10μg/kg (for preventing side effects of neostigmine)
040EG001

Harm

What it counts
Total, serious adverse events
Time frame

Source ClinicalTrials.gov

Trial

Title
Effectiveness of Sugammadex in LMS Surgery
NCT number
NCT02329964
Phases
PHASE4
Conditions
Muscle Relaxation
Interventions
Sugammadex, Neostigmine
Lead sponsor
Korea University Anam Hospital
Results first posted
2015-09-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02329964-sae